1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Myovant/Pfizer Launch Myfembree With An Emphasis On Building Uterine Fibroid Awareness

 
• By Jessica Merrill

Myovant CEO David Marek talked to Scrip about why the companies believe patients and physicians will choose Myfembree over AbbVie's Oriahnn.

megaphone
Myovant and Pfizer will be trying to raise awareness of uterine fibroids • Source: Alamy

Myovant Sciences Ltd. and Pfizer Inc. will launch Myfembree (relugolix/estradiol/norethindrone acetate) in June for heavy menstrual bleeding associated with uterine fibroids after receiving US Food and Drug Administration approval, but the partners will need to overcome some barriers that have limited the commercial success of a similar rival – AbbVie Inc.'s Oriahnn (elagolix/estradiol/norethindrone acetate).

Myovant CEO David Marek and chief medical officer Juan Camilo Arjona Ferreira talked to Scrip on 27 May about how...

More from Immunological

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from Therapy Areas

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.